Bursztyn M, Douer D, Ramot B
Department of Medicine D, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Isr J Med Sci. 1987 Nov;23(11):1140-4.
Thirty-five patients with myelodysplastic syndromes were retrospectively classified according to the FAB classification (French-American-British Cooperative Study Group). Their prognosis was found to be dependent mainly on the presence of blasts in bone marrow examination. Those with an excess of blasts in their bone marrow had a median survival of 30 months in contrast to 66 months in those without blasts. These results were compared with those of seven recent reported series.
根据法国-美国-英国协作研究组（FAB分类法）对35例骨髓增生异常综合征患者进行回顾性分类。发现其预后主要取决于骨髓检查中原始细胞的存在情况。骨髓中原始细胞过多的患者中位生存期为30个月，而无原始细胞的患者中位生存期为66个月。将这些结果与最近报道的7个系列研究结果进行了比较。
